Prima BioMed (NASDAQ:IMMP) Stock Price Breaks Below 50-Day Moving Average – Should You Sell?

Posted by George Bondi on Sep 26th, 2026

Shares of Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report) passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.37 and traded as low as $0.2565. Prima BioMed shares last traded at $0.2620, with a volume of 241,265 shares changing hands.

Analyst Ratings Changes

IMMP has been the subject of a number of analyst reports. Jefferies Financial Group raised shares of Prima BioMed from a “hold” rating to a “strong-buy” rating in a report on Monday, September 14th. Maxim Group upgraded shares of Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Prima BioMed in a research note on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.50.

View Our Latest Report on IMMP

Prima BioMed Stock Up 0.6%

The business’s 50 day moving average price is $0.36 and its 200-day moving average price is $0.47.

Prima BioMed’s stock is set to reverse split before the market opens on Monday, September 28th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, September 27th.

Prima BioMed (NASDAQ:IMMP – Get Free Report) last posted its earnings results on Thursday, July 30th. The biotechnology company reported ($0.09) earnings per share for the quarter. The company had revenue of $3.68 million for the quarter.

Prima BioMed Company Profile

(Get Free Report)

Prima BioMed Limited was an Australian biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.

Its lead development program was eftilagimod alpha, also known as IMP321, a soluble LAG-3 protein intended to stimulate antigen-presenting cells and support broader immune responses. Prima BioMed evaluated the therapy in combination with existing cancer treatments, including chemotherapy and immune checkpoint inhibitors, across several solid-tumor indications.

The company conducted clinical-development activities internationally, including in Australia, Europe and the United States.